Contact Us

Journal-based CME Course: Long-term Immunogenicity of BNT162b2 Vaccine in Patients With Solid Tumors

| Print
Activity

Activity ID

9537

Expires

April 22, 2025

Format Type

Journal-based

CME Credit

1

Fee

$30

CME Provider: JAMA Oncology

Description of CME Course

This cohort study examines cellular and humoral pathways at 6 months after BNT162b2 COVID-19 vaccination in patients with cancer who were receiving active antineoplastic treatment.

Disclaimers

1. This activity is accredited by the American Medical Association.
2. This activity is free to AMA members.

Register for this Activity

ABMS Member Board Approvals by Type
More Information
Commercial Support?
No

NOTE: If a Member Board has not deemed this activity for MOC approval as an accredited CME activity, this activity may count toward an ABMS Member Board’s general CME requirement. Please refer directly to your Member Board’s MOC Part II Lifelong Learning and Self-Assessment Program Requirements.

Keywords

Oncology, Public Health, Vaccination, Coronavirus (COVID-19)

Competencies

Medical Knowledge

CME Credit Type

AMA PRA Category 1 Credit

DOI

10.1001/jamaoncol.2022.1467

View All Activities by this CME Provider

The information provided on this page is subject to change. Please refer to the CME Provider’s website to confirm the most current information.